Patients with chronic hepatitis C virus (HCV) experience severe morbidity and mortality, including potentially fatal cirrhosis or liver cancer (SN Compr Clin Med 2020;2[12]:2808-2815). Although more than 95% of HCV can be cured with direct-acting antivirals (DAAs), confirming effective treatment requires a test for sustained virologic response (SVR) at least 12 weeks after completion of therapy, and many patients do not complete this testing regimen. When specialty pharmacists